ArticleFrontiers in microbiology2025
Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissions.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In advanced chronic liver disease (ACLD) patients, bacterial infections with multidrug-resistant Gram-negative bacteria (MDRGN) can progress to acute-on-chronic liver failure (ACLF) with high mortality rates. Particularly carbapenem-resistant Gram-negative bacteria (CR-GN) pose a significant threat due to limited antibiotic treatment options. However, non-carbapenem drug-resistant Gram-negative bacteria (NCR-DRGN) are clinically highly relevant, as they occur more frequently and may serve as precursors to CR-GN. This study aims to assess the prevalence, resistance mechanisms, and transmission dynamics of NCR-DRGN in ACLD patients including those with ACLF. Materials and methods: A prospective, single-center study was conducted at University Hospital Frankfurt. Over 32 months, ACLD patients were screened for NCR-DRGN by routine microbiology techniques. Whole-genome sequencing (WGS) of isolated bacteria was performed to analyze genetic diversity, resistance, and transmission patterns. Epidemiological links were explored through patient chart reviews. Results: NCR-DRGN were found in 12.1% ( Conclusion: NCR-DRGN are prevalent in ACLD patients, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.